Second line therapy for metastatic urothelial carcinoma. Clinical case of vinflunine use
A. A. Gritskevich,
A. Yu. Popov,
I. G. Rusakov,
E. K. Vozniy,
V. A. Makarov,
D. I. Gridnev,
T. P. Baitman,
S. V. Mishugin,
I. V. Novikova,
S. V. Khromova https://doi.org/10.21518/2079-701X-2022-16-9-95-103
Abstract
Urothelial cancer occupies a significant place in the routine practice of cancer treatment. Systemic antitumor treatment of patients with metastatic urothelial cancer in the first line is currently well studied, has its own standards, implemented in clinical practice. However, the problem of choosing antitumor treatment for patients with metastatic urothelial cancer in the second line remains relevant. Vinflunine is one of the treatment options for such patients. This article presents the case of successful treatment of metastatic urothelial cancer in the second line with vinflunine. A 63-year-old patient with a diagnosis of C65 Urothelial cancer of the pelvis of the left kidney T3N0M1, stage IV, bone metastases. Condition after cytoreductive left-sided nephrectomy, para-aortic lymphadenectomy from 04/16/2021. Concomitant pathology: Anemia. Diabetes mellitus type 2 Hypertonic disease. As the 1st line of treatment, 6 courses of CT were performed according to the scheme: Cisplatin + Gemcitabine. The effect was evaluated according to MSCT data of 3 zones and bone scintigraphy in accordance with Recist 1.1. The best response was obtained after the 4th cycle in August 2021 in the form of stabilization. October 2021 follow-up examination revealed progression. Since October 2021, chemotherapy of the 2nd line with Vinflunin is carried out in mono mode. All AEs are well controlled and do not require discontinuation of the drug. According to the results of the control examination, stabilization was achieved. Thereby vinflunine has been shown to be effective as a second-line treatment for platinum-resistant recurrent urothelial cancer.
About the Authors
A. A. Gritskevich
Vishnevsky National Medical Research Center of Surgery; Peoples' Friendship University of Russia
Russian Federation
Russian Federation
Alexander A. Gritskevich - Dr. Sci. (Med.), Head of the Department of Urology, Vishnevsky National Medical Research Center of Surgery; Professor of the Department of Urology with the Course of Oncology, Radiology and Andrology of the Medical Institute, Peoples' Friendship University of Russia.
27, Bolshaya Serpukhovskaya St., Moscow, 117997; 6, Miklukho-Maklai St., Moscow, 117198.
A. Yu. Popov
Vishnevsky National Medical Research Center of Surgery
Russian Federation
Russian Federation
Anatoly Yu. Popov - Cand. Sci. (Med.), Head of the Department of Anticancer Drug Therapy, Vishnevsky National Medical Research Center of Surgery.
27, Bolshaya Serpukhovskaya St., Moscow, 117997.
I. G. Rusakov
Pletnev City Clinical Hospital
Russian Federation
Russian Federation
Igor G. Rusakov - Dr. Sci. (Med.), Professor, Deputy Chief Physician for Oncology, Pletnev City Clinical Hospital.
32, 11th Parkovaya St., Moscow, 105077.
E. K. Vozniy
Pletnev City Clinical Hospital
Russian Federation
Russian Federation
Eduard K. Vozniy - Dr. Sci. (Med.), Рrofessor, Consultant, Department of Chemotherapy, Pletnev City Clinical Hospital.
32, 11th Parkovaya St., Moscow, 105077.
V. A. Makarov
Vishnevsky National Medical Research Center of Surgery
Russian Federation
Russian Federation
Vladislav A. Makarov - Cand. Sci. (Med.), Oncologist, Department of Anticancer Drug Therapy, Vishnevsky National Medical Research Center of Surgery.
27, Bolshaya Serpukhovskaya St., Moscow, 117997.
D. I. Gridnev
Vishnevsky National Medical Research Center of Surgery
Russian Federation
Russian Federation
Danila I. Gridnev - Oncologist, Department of Anticancer Drug Therapy, Vishnevsky National Medical Research Center of Surgery.
27, Bolshaya Serpukhovskaya St., Moscow, 117997.
T. P. Baitman
Vishnevsky National Medical Research Center of Surgery
Russian Federation
Russian Federation
Tatiana P. Baitman - Postgraduate Student, Vishnevsky National Medical Research Center of Surgery.
27, Bolshaya Serpukhovskaya St., Moscow, 117997.
S. V. Mishugin
Pletnev City Clinical Hospital
Russian Federation
Russian Federation
Sergey V. Mishugin - Cand. Sci. (Med.), Head of the Oncourological Department, Pletnev City Clinical Hospital.
32, 11th Parkovaya St., Moscow, 105077.
I. V. Novikova
Pletnev City Clinical Hospital
Russian Federation
Russian Federation
Inna V. Novikova - Doctor of Oncourology Department, Pletnev City Clinical Hospital.
32, 11th Parkovaya St., Moscow, 105077.
S. V. Khromova
Vishnevsky National Medical Research Center of Surgery
Russian Federation
Russian Federation
Stanislava V. Khromova - Resident, Vishnevsky National Medical Research Center of Surgery.
27, Bolshaya Serpukhovskaya St., Moscow, 117997.
References
1. Kaprin A.D., Starinskiy V.V., Schachzadova O.A. (eds.). Malignant neoplasms in Russia in 2020 (morbidity and mortality). Moscow; 2021. 252 p. (In Russ.) Available at: https://oncology-association.ru/wp-content/uploads/2021/11/zis-2020-elektronnaya-versiya.pdf?ysclid=l3badk8twu.
2. Galsky M.D., Hahn N.M., Rosenberg J., Sonpavde G., Hutson T., Oh W.K. et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet. Oncology. 2011;12(3):211—214. https://doi.org/10.1016/S1470-2045(10)70275-8.
3. Galsky M.D., Hahn N.M., Rosenberg J., Sonpavde G., Hutson T., Oh W.K. et al. Treatment of patients with metastatic urothelial cancer “unfit” for Cisplatin-based chemotherapy.J Clin Oncol. 2011;29(17):2432-2438. https://doi.org/10.1200/JCO.2011.34.8433.
4. Hussain S.A., Palmer D.H., Lloyd B., Collins S.I., Barton D., Ansari J., James N. D. A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer. Oncol Lett. 2012;3(4):855-859. https://doi.org/10.3892/ol.2012.563.
5. Hussain S.A., Stocken D.D., Riley P., Palmer D.H., Peake D.R., Geh J.I. et al. A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. Br J Cancer. 2004;91(5):844-849. https://doi.org/10.1038/sj.bjc.6602112.
6. Sternberg C.N., Calabro F., Pizzocaro G., Marini L., Schnetzer S., Sella A. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer. 2001;92(12):2993-2998. https//doi.org/10.1002/1097-0142(20011215)92:12<2993::aid-cncr10108>3.0.co;2-2.
7. Meluch A.A., Greco F.A., Burris H.A. 3rd, O'Rourke T., Ortega G., Steis R.G. et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol. 2001;19(12):3018-3024. https://doi.org/10.1200/JCO.2001.19.12.3018.
8. Calabro F., Lorusso V., Rosati G., Manzione L., Frassineti L., Sava T. et al. Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma. Cancer. 2009;115(12):2652-2659. https://doi.org/10.1002/cncr.24313.
9. De Santis M., Wiechno P.J., Bellmunt J., Lucas C., Su W.C., Albiges L. et al. Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1). Ann Oncol. 2016;27(3):449-454. https//doi.org/10.1093/annonc/mdv609.
10. Galsky M.D., Arija J., Bamias A., Davis I.D., De Santis M., Kikuchi E. et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre,randomised,placebo-controlled phase 3 trial. Lancet. 2020;395(10236):1547-1557. https//doi.org/10.1016/S0140-6736(20)30230-0.
11. Powles T., Csoszi T., Ozguroglu M., Matsubara N., Geczi L., Cheng S.Y. et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(7):931-945. https//doi.org/10.1016/S1470-2045(21)00152-2.
12. Powles T., van der Heijden M.S., Castellano D., Galsky M.D., Loriot Y., Petrylak D.P. et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2020;21(12):1574-1588. https//doi.org/10.1016/S1470-2045(20)30541-6.
13. Oing C., Rink M., Oechsle K., Seidel C., von Amsberg G., Bokemeyer, C. Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature. J Urol. 2016;195(2):254-263. https//doi.org/10.1016/j.juro.2015.06.115.
14. Raggi D., Miceli R., Sonpavde G., Giannatempo P., Mariani L., Galsky M.D. et al. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. Ann Oncol. 2016;27(1):49-61. https//doi.org/10.1093/annonc/mdv509.
15. Albers P., Park S.I., Niegisch G., Fechner G., Steiner U., Lehmann J. et al. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann Oncol. 2011;22(2):288-294. https://doi.org/10.1093/annonc/mdq398.
16. Fechner G., Siener R., Reimann M., Kobalz L., Albers P. Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). Int J Clin Pract. 2006;60(1):27-31. https//doi.org/10.1111/j.1742-1241.2005.00663.x.
17. Bellmunt J., Theodore C., Demkov T., Komyakov B., Sengelov L., Daugaard G. et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27(27):4454-4461. https//doi.org/10.1200/JCO.2008.20.5534.
18. Zhavlor: new opportunities in the treatment of patients with metastatic bladder cancer. Anniversary Congress of the Russian Society of Oncourologists. Satellite symposium of the Pierre Fabre company. Effective Pharmacotherapy. 2015;(3):34-38. (In Russ.) Available at: https://umedp.ru/upload/iblock/6a5/onko_03_2015.pdf.
19. Castellano D., Puente J., de Velasco G., Chirivella I., Lopez-Criado P., Mohedano N. et al. Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice. BMC Cancer. 2014;14:779. https://doi.org/10.1186/1471-2407-14-779.
20. Medioni J., Di Palma M., Guillot A., Spaeth D., Theodore C. Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study. BMC Cancer. 2016;16:217. https://doi.org/10.1186/s12885-016-2262-9.
21. Retz M., de Geeter P., Goebell P.J., Matz U., de Schultz W., Hegele A. Vinflunine in routine clinical practice for the treatment of advanced or metastatic urothelial cell carcinoma - data from a prospective, multicenter experience. BMC Cancer. 2015;15:455. https://doi.org/10.1186/s12885-015-1434-3.
22. Volkova M.I., Chernyaev V.A., Matveev V.B., Alekseev B.Ya., Nyushko K.M., Bolotina L.V. et al. The efficacy and safety of vinflunine in second-line therapy of patients with disseminated transitional cell carcinoma of the urinary tract in clinical practice. Onkourologiya. 2016;(3):74-81. (In Russ.) https://doi.org/10.17650/1726-9776-2016-12-3-74-81.
Review
For citations:
Gritskevich AA, Popov AY, Rusakov IG, Vozniy EK, Makarov VA, Gridnev DI, Baitman TP, Mishugin SV, Novikova IV, Khromova SV. Second line therapy for metastatic urothelial carcinoma. Clinical case of vinflunine use. Meditsinskiy sovet = Medical Council. 2022;(9):95-103. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-9-95-103
Views:
472
Email this article 